Peer Review History
| Original SubmissionNovember 28, 2024 |
|---|
|
Dear Dr. Mancini, Please submit your revised manuscript by Aug 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Vijayaprasad Gopichandran Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. 3. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. Additional Editor Comments: Kindly pay close attention to the two reviewers' comments and revise accordingly. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** Reviewer #1: This is a very interesting paper tackling a relevant research area. The methodology used is very appropriate for addressing the intended objectives. The discussions and conclusions were aligned to the results. Ethics approval was sought, and participants had the opportunity to provide consent for participation in line with ethics requirements. Reviewer #2: Lines 90 & 91, and lines 108-109 – The first objective of the study reads “to assess whether providing brief information on CTs improved the general impression of and willingness to participate in CTs in a sample of socioeconomically disadvantaged” whereas the exclusion criteria say “persons who reported that they had never heard of CTs in the survey questionnaire were 108 secondarily excluded from the analysis.” If people were not provided information, how are they expected to participate irrespective of the method of information? Please explain why this was given as an exclusion factor Line 100, page 4 – Please provide brief information on what is meant by the IPSOS i-Say sampling panel Lines 144-149, page 5 – The authors mention 3 groups, but there is no explanation on why there are 3 groups in the study, and what the 3 groups are. Please provide the rationale Lines 145-147, page 5 – There is no explanation on why a tabular form was chosen for the information regarding CTs. What was the rationale behind choosing the tabular formats? Lines 145-147, page 5 – Why are there two tabular formats, and why was it pooled later during the analysis? Lines 160-162, page 6 – Why was group 1 excluded from the analysis? Please provide an explanation Table 1, page 7 – While the study objective is to see whether there is an improved willingness to participate in CT and the general impression about the CTs, is there a baseline captured on similar information? Without a baseline, how could the comparison be done to say whether such a method of information would improve the participation in CT? Lines 46-47, page 1 – the Discussion/Conclusion section of the abstract that “The initial impression of CTs was quite poor in this socioeconomically disadvantaged sample, but improved after the brief information note on CTs was provided”. Where is the corresponding data for this? Any baseline assessment percentages and comparison with the post test? Lines 95-98, page 4 – How did the participant selection happen? Was there any particular method of sampling used to select the participants? Lines 312-314, page 12 – “In our study, providing individuals with brief pertinent information helped to improve their general impression of CTs and, to some extent, their willingness to participate in them” – does it corresponds to the tabular form or textual form? Reviewer #3: The study documents the effect of presenting information about clinical trials in different formats (textual vs tabular) on the perceptions and hypothetical willingness of socioeconomically disadvantaged individuals in France to participate in such trials. The research is relevant and timely, addressing an important gap in health communication and equity in clinical trial participation. Comment 1: The use of the term “participation” in the title might be misleading, as actual clinical trial participation was not measured. Consider revising the title to reflect the assessment of hypothetical willingness, such as: “Providing brief information on clinical trials in appropriate formats may improve impressions and willingness to participate among socioeconomically disadvantaged people in France.” Comment 2: Please consider adding a brief introduction of the definition of clinical trial for a broader audience. Comment 3: On Page 3, line 61, the percentage value “28.0%” is duplicated. Please correct this typographical error. Comment 4: The repeated use of the phrase “many studies” in the introduction contributes to a monotonous tone. Rephrase it for improved readability. Comment 5: On Page 4, line 89, consider rephrasing the sentence “focused specifically on the second information step listed above” to directly state the study’s objectives. Comment 6: Provide a brief description of the IPSOS i-Say panel, including the total number invited, response rate, participant incentives, and how representative the sample is of socioeconomically disadvantaged individuals in France. Comment 7: The sentence “Included persons who reported that they had never heard of CTs… were secondarily excluded from the analysis” can be moved from the methodology to the Results section to improve logical flow. The term “secondary exclusion criterion” can be removed. Comment 8: Briefly describe the validity of the tools used (e.g., SILS, SNS3, table comprehension score) and their appropriateness for the target population. Comment 9: Clarify whether the information notes were delivered via the same online platform as the survey. Comment 10: Please confirm whether data were collected anonymously and describe the measures taken to ensure data security and confidentiality. Comment 11: On Page 7, line 185, there appears to be a discrepancy regarding the proportion of participants with chronic conditions. Table 1 lists 35%, while the text mentions 37%. Please ensure consistency between tables and text. Comment 12: On Page 8, line 200, replace vague fractions such as “three-quarters” with exact proportions or percentages and revise throughout the manuscript (e.g., “two-fifths,” “four-fifths”). Comment 13: On Page 10, line 236, please verify and correct any inconsistencies between the regression coefficients mentioned in the text and those reported in Table S2 Comment 14: Consider elaborating more explicitly on potential biases in your study, such as selection bias, social desirability bias, and response bias, particularly given the online, self-reported nature of the survey. Comment 15: Reference 10 should be translated and formatted as: Schultz, É., Ward, J.K., Touzani, R., Rouquette, A. and Mancini, J. (2024). Between Health and Science: Health Literacy and the Perception of Medical Research. Santé Publique, 36(3), 103–108. https://doi.org/10.3917/spub.243.0103 ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: RAJESWARAN THIAGESAN Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
Providing brief information on clinical trials in appropriate formats may improve impressions and willingness to participate among socioeconomically disadvantaged people in France. PONE-D-24-54157R1 Dear Dr. Mancini, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Vijayaprasad Gopichandran Academic Editor PLOS ONE Additional Editor Comments (optional): Well revised. Reviewers' comments: |
| Formally Accepted |
|
PONE-D-24-54157R1 PLOS ONE Dear Dr. Mancini, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Vijayaprasad Gopichandran Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .